Kite Pharma, Inc. – Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma

Submitted By:
Published Date:
January 25, 2020

Access Program Information

This is a multicenter, open-label expanded access protocol for the treatment of subjects
with relapsed/refractory transplant ineligible aggressive NHL.

Rare Disease:
Spondyloepiphyseal dysplasia congenita Spondyloepiphyseal dysplasia- congenita